[title missed]

Corresponding author: 李洛华, 1522656847@qq.com

DOI: 10.12201/bmr.202506.00031

•  

  Abstract: [abstract missed]

  Key words: ; ; 

  Submit time: 14 June 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• DuYuPeng, LinYan. Exploration of Diagnostic and Treatment Experience in Two Cases of Idiopathic Retroperitoneal Fibrosis. 2024. doi: 10.12201/bmr.202410.00077

  Guan Wei, Xue Xiaoming. Progress of Trditional Chinese Medicine Targeting Alveolar Epithelial Cell Senescence in the Treatment of Pulmonary Fibrosis. 2025. doi: 10.12201/bmr.202506.00012

  Zhang Ye, Yang Li. The experience of American peritoneal dialysis favored policy and its enlightenment to China. 2022. doi: 10.12201/bmr.202206.00011

  zhaofenqin. . 2025. doi: 10.12201/bmr.202501.00040

  Shen Yanping. Research progress of peritoneal transport function and microinflammation. 2024. doi: 10.12201/bmr.202412.00066

  Li Junyuan, Zhang Bin, He Yong. . 2024. doi: 10.12201/bmr.202406.00011

  Cai Xudong. Macrophage Polarization Affects Chronic Kidney Disease:Based on Theory of “Harmful Hyperactivity and Responding Inhibition”. 2024. doi: 10.12201/bmr.202407.00027

  guoxiaochen, wangpengfei, chenxiu, wuxinyao, zouchunpengchun, 徐茂晟. The value of SWE in early liver and kidney fibrosis in MAFLD. 2024. doi: 10.12201/bmr.202409.00010

  Lin ZhiFeng, ZHANG ChuJian, LIU Dong, Kong YiJing. To explore the optimal intervention time of 1.25 (OH) 2D3 to protect renal interstitialfibrosis based on NF-κB inflammatory pathway. 2025. doi: 10.12201/bmr.202504.00063

  HANG Yu-jie, CHEN Kun, LIU Qian-yu, ZHANG Yu-bin, XU Liang, ZHANG Li-xue, BAI Jing-ya▲. Research progress of biomarkers for renal fibrosis. 2024. doi: 10.12201/bmr.202411.00072

• ID	Submit time	Number	Download
  1	2025-05-29	bmr.202506.00031V1	Download

• Public  Anonymous  To author only Submit Comments